Using FlexPen® is much easier than using the syringe. It's great. I can just carry it around in my pocket and take a shot when I need it. If I forget my glasses, I can count the clicks to know how many units I'm taking. Everything about the FlexPen® is great. It's convenient. You can't tell it's a pen or a needle. It looks like a pen in your pocket. It's the best thing since, you know, Babe Ruth.
The design of it just lets me unbutton my shirt and give myself a shot, and it's over with before anybody knows it. I'm not holding up a bottle, holding up a syringe. It's convenient. You don't have to draw anything out of a vial. You just dial up what you want, pull the cap off, screw a needle on, and it's done. The design of the FlexPen® definitely makes me feel more comfortable about handling my diabetes
NovoFine® needles
- The finishing touch to diabetes care
Our state-of-the-art technology has made NovoFine® needles more comfortable than ever and the perfect finishing touch to diabetes care.
Our easy-to-use NovoFine® needles are among the shortest and thinnest available.
NovoFine® short needles offer a safe, effective insulin delivery, and Extra Thin Wall Technology improves insulin flow for a more comfortable injection.
With NovoFine® needles as a part of the Novo Nordisk insulin delivery system, patients can experience the ultimate in injection comfort and confidence.
NovoFine® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk in short
Novo Nordisk sales totalled DKK 44.831 million (EUR 5.614 million) in 2007. With headquarters in Denmark, Novo Nordisk employs approximately 25.500 full-time employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Triple bottom line focus
Novo Nordisk is committed to developing its business towards ecological, social and economic sustainability. This commitment is demonstrated through its values and its environmental and social responsibility policies.
Stock exchange listings
Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.
Our Vision
Our Vision paints a picture of what Novo Nordisk wants to achieve as a company - our place in the market and our overall goals in relation to patients, society and employees.
The Charter
How we act is described in the Charter. The Charter describes our Values, Commitments and Fundamentals - our basic management principles. Novo Nordisk has adopted the Charter for companies in the Novo Group - we commit ourselves to act inside this framework.
Back to top
Novo Nordisk sales totalled DKK 44.831 million (EUR 5.614 million) in 2007. With headquarters in Denmark, Novo Nordisk employs approximately 25.500 full-time employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Triple bottom line focus
Novo Nordisk is committed to developing its business towards ecological, social and economic sustainability. This commitment is demonstrated through its values and its environmental and social responsibility policies.
Stock exchange listings
Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.
Our Vision
Our Vision paints a picture of what Novo Nordisk wants to achieve as a company - our place in the market and our overall goals in relation to patients, society and employees.
The Charter
How we act is described in the Charter. The Charter describes our Values, Commitments and Fundamentals - our basic management principles. Novo Nordisk has adopted the Charter for companies in the Novo Group - we commit ourselves to act inside this framework.
Back to top
